It will be the first time interim results from the global, prospective verITI-8 study of rFVIIIFc for first-time ITI will be presented.
STOCKHOLM, June 25, 2019 /PRNewswire/ -- Sobi™ presents data at the ISTH 2019: The 27th Congress of the International Society on Thrombosis and Haemostasis, Melbourne, Australia, 6 – 10 July 2019, focusing on the use of Elocta® and Alprolix® in clinical settings such as treatment switches from on demand to prophylaxis and immune tolerance induction (ITI). The reported outcomes include annualised bleeding rates, quality of life as well as joint health. It will be the first time interim results from the global, prospective verITI-8 study of rFVIIIFc for first-time ITI will be presented. We will also present data showing the pain and mental burden associated with haemophilia in the real world setting. “Previous communications have focused on the safety and efficacy of our products. Now we take one step further and show how our products can help to raise the standard of care in various situations in life, liberating life and expanding the possibilities for people with haemophilia,” says Armin Reininger, Head of Medical and Scientific Affairs at Sobi. “By increasing the scientific evidence and the understanding of the clinical value of our extended half-life products in all patient groups living with haemophilia, we maintain our focus on research and an approach to treatment that reflects a meaningful difference for patients, allowing them to live a life beyond haemophilia”. Abstracts:
All abstracts can be accessed via the official ISTH website. About Elocta® Elocta is approved and marketed by Sobi for the treatment of haemophilia A in the EU, Iceland, Kuwait, Liechtenstein, Norway, Saudi Arabia and Switzerland. It is approved and marketed as ELOCTATE® [Antihemophilic Factor (Recombinant), Fc Fusion Protein] by Sanofi in the United States, Japan and Canada. It is also approved in Australia, New Zealand, Brazil and other countries, where Sanofi has the marketing rights. As with any factor replacement therapy, allergic-type hypersensitivity reactions and development of inhibitors may occur in the treatment of haemophilia A. Inhibitor development has been observed with Elocta, including in previously untreated patients. For more information, please see the full U.S. prescribing information for ELOCTATE. Note that the indication for previously untreated patients and ITI treatment is not included in the EU Product Information for Elocta. About Alprolix® Alprolix is approved and marketed by Sobi for the treatment of haemophilia B in the EU, Iceland, Kuwait, Liechtenstein, Norway, Saudi Arabia and Switzerland. It is also approved in the United States, Canada, Japan, Australia, New Zealand, Brazil and other countries where Sanofi has the marketing rights. Allergic-type hypersensitivity reactions and development of inhibitors have been observed with Alprolix in the treatment of haemophilia B, including in previously-untreated patients. For more information, please see the full U.S. prescribing information for Alprolix. Note that the indication for previously-untreated patients is not included in the EU Product Information. About haemophilia A and B People with haemophilia A or B experience bleeding episodes that can cause pain, irreversible joint damage and life-threatening haemorrhages. Prophylactic infusions of factor VIII or IX can temporarily replace the clotting factors that are needed to control bleeding and prevent new bleeding episodes.[ii] The World Federation of Hemophilia recommends prophylaxis as the optimal therapy as it can prevent bleedings and joint destruction.[iii] About the Sobi and Sanofi collaboration About Sobi™ For more information please contact Linda Holmström, Corporate Communications & Investor Relations [i] The WFH Annual Global Survey 2017 https://www.wfh.org/en/data-collection [ii] World Federation of Hemophilia. About Bleeding Disorders – Frequently Asked Questions. Available at: http://www.wfh.org/en/page.aspx?pid=637. Accessed on May 23, 2017. [iii] World Federation of Hemophilia. Guideline for the management of hemophilia, 2nd edition. Available at: http://www1.wfh.org/publication/files/pdf-1472.pdf. Accessed on May 23, 2017. This information was brought to you by Cision http://news.cision.com The following files are available for download:
SOURCE Swedish Orphan Biovitrum AB | ||||
Company Codes: Bloomberg:SOBI@SS, ISIN:SE0000872095, RICS:SOBI.ST, Stockholm:SOBI |